» Articles » PMID: 1378449

Identification of a Specific Glycoprotein Ligand for P-selectin (CD62) on Myeloid Cells

Overview
Journal J Cell Biol
Specialty Cell Biology
Date 1992 Jul 1
PMID 1378449
Citations 131
Authors
Affiliations
Soon will be listed here.
Abstract

P-selectin (CD62, GMP-140, PADGEM), a Ca(2+)-dependent lectin on activated platelets and endothelium, functions as a receptor for myeloid cells by interacting with sialylated, fucosylated lactosaminoglycans. P-selectin binds to a limited number of protease-sensitive sites on myeloid cells, but the protein(s) that carry the glycans recognized by P-selectin are unknown. Blotting of neutrophil or HL-60 cell membrane extracts with [125I]P-selectin and affinity chromatography of [3H]glucosamine-labeled HL-60 cell extracts were used to identify P-selectin ligands. A major ligand was identified with an approximately 250,000 M(r) under nonreducing conditions and approximately 120,000 under reducing conditions. Binding of P-selectin to the ligand was Ca2+ dependent and was blocked by mAbs to P-selectin. Brief sialidase digestion of the ligand increased its apparent molecular weight; however, prolonged digestion abolished binding of P-selectin. Peptide:N-glycosidase F treatment reduced the apparent molecular weight of the ligand by approximately 3,000 but did not affect P-selectin binding. Western blot and immunodepletion experiments indicated that the ligand was not lamp-1, lamp-2, or L-selectin, which carry sialyl Le(x), nor was it leukosialin, a heavily sialylated glycoprotein of similar molecular weight. The preferential interaction of the ligand with P-selectin suggests that it may play a role in adhesion of myeloid cells to activated platelets and endothelial cells.

Citing Articles

Antibody blockade of the PSGL-1 immune checkpoint enhances T-cell responses to B-cell lymphoma.

Pereira J, Arede L, Ferreira F, Matos A, Pereira D, Santos R Leukemia. 2024; 39(1):178-188.

PMID: 39455852 DOI: 10.1038/s41375-024-02446-w.


Preclinical Efficacy of VTX-0811: A Humanized First-in-Class PSGL-1 mAb Targeting TAMs to Suppress Tumor Growth.

Novobrantseva T, Manfra D, Ritter J, Razlog M, ONuallain B, Zafari M Cancers (Basel). 2024; 16(16).

PMID: 39199551 PMC: 11352552. DOI: 10.3390/cancers16162778.


Macrophages and platelets in liver fibrosis and hepatocellular carcinoma.

Casari M, Siegl D, Deppermann C, Schuppan D Front Immunol. 2023; 14:1277808.

PMID: 38116017 PMC: 10728659. DOI: 10.3389/fimmu.2023.1277808.


Bleeding and Thrombosis in Multiple Myeloma: Platelets as Key Players during Cell Interactions and Potential Use as Drug Delivery Systems.

Kulkarni A, Bazou D, Santos-Martinez M Int J Mol Sci. 2023; 24(21).

PMID: 37958838 PMC: 10647631. DOI: 10.3390/ijms242115855.


PSGL-1 Blockade Induces Classical Activation of Human Tumor-associated Macrophages.

Kauffman K, Manfra D, Nowakowska D, Zafari M, Nguyen P, Phennicie R Cancer Res Commun. 2023; 3(10):2182-2194.

PMID: 37819238 PMC: 10601817. DOI: 10.1158/2767-9764.CRC-22-0513.


References
1.
Cummings R, Kornfeld S, Schneider W, Hobgood K, Tolleshaug H, Brown M . Biosynthesis of N- and O-linked oligosaccharides of the low density lipoprotein receptor. J Biol Chem. 1983; 258(24):15261-73. View

2.
True D, Singer M, Lasky L, Rosen S . Requirement for sialic acid on the endothelial ligand of a lymphocyte homing receptor. J Cell Biol. 1990; 111(6 Pt 1):2757-64. PMC: 2116434. DOI: 10.1083/jcb.111.6.2757. View

3.
Fukuda M, Spooncer E, Oates J, Dell A, Klock J . Structure of sialylated fucosyl lactosaminoglycan isolated from human granulocytes. J Biol Chem. 1984; 259(17):10925-35. View

4.
Varki A, Diaz S . A neuraminidase from Streptococcus sanguis that can release O-acetylated sialic acids. J Biol Chem. 1983; 258(20):12465-71. View

5.
McEver R, Martin M . A monoclonal antibody to a membrane glycoprotein binds only to activated platelets. J Biol Chem. 1984; 259(15):9799-804. View